by Patel BD, Uppal R, Pulakundam N, Patel JP, Ramanathan V, Ameta R, Launay D, Braillard S.
Bioanalysis, September 2019
by Wijnant G-J, Croft SL, de la Flor R, Alavijeh M, Yardley V, Braillard S, Mowbray C, Van Bocxlaer K.
Antimicrobial Agents and Chemotherapy, August 2019
The Week [6 August 2019]
“Patients cured of kala-azar can still transmit disease, says study”
Agência Brasil [31 July 2019]
“Pesquisadores testam novo tratamento contra leishmaniose” – “Researchers test a new treatment for leishmaniasis”
The Telegraph [23 July 2019]
“Patients cured of deadly tropical disease can infect others for years, researchers warn”
The Hindu Business Line [23 July 2019]
“Study warns `kala azar’ patients can infect others even after treatment”
Could a form of leishmaniasis challenge elimination efforts in India?
Geneva/New Delhi – 22 July 2019
Results show that a skin condition known as post-kala-azar dermal leishmaniasis (PKDL) could be a threat to elimination of leishmaniasis in South Asia
The results of an innovative “infectivity” study conducted by DNDi and the International Centre for Diarrhoeal Disease Research, Bangladesh confirm that people successfully treated for visceral leishmaniasis in South Asia can still infect others if they develop a skin condition known as PKDL.
The India Saga [22 July 2019]
“New Study Shows Patients Treated For ‘Kala-Azar’ Can Still Transmit The Disease”
Nature India [22 July 2019]
“Skin lesions are reservoirs for kala-azar infection”
The Pioneer [21 July 2019]
“Post-Kala Azar skin disease a reservoir of parasites”
- The 2nd LEAP Scientific Conference has been postponed. The new dates will be announced once they are available.
by Mondal D, Bern C, Ghosh D, Rashid M, Molina R, Chowdhury R, Nath R, Ghosh P, Chapman L, Alim A, Bilbe G, Alvar J.
Clinical Infectious Diseases, July 2019
Scientific African Magazine [26 June 2019]
“New treatment offers hope for kala-azar victims who also have HIV”
by Sunyoto T, Potet J, den Boer M, Ritmeijer K, Postigo JAR, Ravinetto R, Alves F, Picado A, Boelaert M.
BMJ Open, May 2019
16-20 September 2019
- DNDi – one symposium on cutaneous leishmaniasis and one on mycetoma
- Nathalie Strub-Wourgaft, NTD Director – panel discussion on the future of research and development, satellite symposium on sleeping sickness
Better than boiling oil or amputation? Stories behind the treatment needs of two of the world’s most neglected tropical diseases, cutaneous leishmaniasis and mycetoma
16 September 2019
- Join us on the sidelines of the 2019 European Congress for Tropical Medicine and International Health for the engaging stories of Pip Stewart, a British adventurer who contracted CL on a record-breaking paddling trip in the Amazon, and two researchers working on the first-ever clinical trial for a fungal mycetoma treatment, Dr Borna Nyaoke, a physician and clinical researcher from DNDi based in Nairobi, Kenya, and Dr Sahar Bakhiet, a microbiologist at the Mycetoma Research Centre in Khartoum, Sudan who works with communities affected by mycetoma.
Congress of the Brazilian Society of Tropical Medicine
28-31 July 2019
Belo Horizonte, Brazil
- DNDi participating in several round tables and doing presentations on Chagas disease, leishmaniasis, and hepatitis C